DRTS
Alpha Tau Medical Ltd
$
2.600
- Overview
- Forecast
- Valuation
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.640
Open
2.640
VWAP
2.61
Vol
30.10K
Mkt Cap
219.68M
Low
2.570
Amount
78.54K
EV/EBITDA(TTM)
--
Total Shares
69.80M
EV
165.21M
EV/OCF(TTM)
--
P/S(TTM)
--
Alpha Tau Medical Ltd is an Israel-based medical technology company that focuses on research, development and commercialization of Alpha DaRT Diffusing Alpha-emitters Radiation Therapy (Alpha DaRT) for the treatment of solid cancer. Company's technology relies on the diffusion of atoms that emit alpha particles within the tumor tissue, and enables alpha radiation to reach the the entire tumor. Precise amounts of radioactive radium-224 affixed that emit short-range alpha radiation enables to damages and kills cancer cells within a short period of time. The Company has one subsidiary Healthcare Capital Corp.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q1
FY2025Q2
FY2025Q3
--
--
-0.127
+15.77%
--
--
-0.122
+10.72%
--
--
-0.118
+17.93%
Estimates Revision
The market is revising No Change the revenue expectations for Alpha Tau Medical Ltd. (DRTS) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -19.50%.
Revenue Estimates for FY2025
No Change
0.00%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-0.37%
In Past 3 Month
Stock Price
Go Down
-19.50%
In Past 3 Month
3 Analyst Rating
181.92% Upside
Wall Street analysts forecast DRTS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for DRTS is 7.33 USD with a low forecast of 5.00 USD and a high forecast of 9.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
181.92% Upside
Current: 2.600
Low
5.00
Averages
7.33
High
9.00
181.92% Upside
Current: 2.600
Low
5.00
Averages
7.33
High
9.00
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2025-04-29
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2025-04-29
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2025-03-17
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2025-03-17
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-11-22
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2024-11-22
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-10-23
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2024-10-23
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-10-11
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2024-10-11
Reiterates
Strong Buy
Reason
HC Wainwright & Co.
Yi Chen
Strong Buy
Reiterates
$9
2024-08-20
Reason
HC Wainwright & Co.
Yi Chen
Price Target
$9
2024-08-20
Reiterates
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Alpha Tau Medical Ltd (DRTS.O) is -5.26, compared to its 5-year average forward P/E of -13.87. For a more detailed relative valuation and DCF analysis to assess Alpha Tau Medical Ltd 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-13.87
Current PE
-5.26
Overvalued PE
-1.61
Undervalued PE
-26.13
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-3.89
Current EV/EBITDA
-3.08
Overvalued EV/EBITDA
0.31
Undervalued EV/EBITDA
-8.09
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
300.05
Current PS
561.96
Overvalued PS
956.69
Undervalued PS
-356.58
Financials
Annual
Quarterly
FY2024Q4
YoY :
+3.33%
-10.27M
Operating Profit
FY2024Q4
YoY :
+28.66%
-9.48M
Net Income after Tax
FY2024Q4
YoY :
+27.27%
-0.14
EPS - Diluted
FY2022Q2
YoY :
+221.47%
-9.12M
Free Cash Flow
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
DRTS News & Events
Events Timeline
2025-04-28 (ET)
2025-04-28
09:05:26
Alpha Tau enters strategic marketing alliance with Oramed
2025-04-28
09:04:22
Oramed announces $36.9M investment and collaboration with Alpha Tau
2025-04-02 (ET)
2025-04-02
08:31:33
Alpha Tau receives FDA approval to start trial for patients with recurrent GBM
Sign Up For More Events
Sign Up For More Events
News
8.5
04-28NewsfilterOramed Pharmaceuticals Announces $36.9 Million Investment and Strategic Collaboration with Alpha Tau Medical
8.5
04-28NewsfilterAlpha Tau Announces Closing of $36.9 Million Registered Direct Offering and Strategic Marketing Alliance with Oramed Pharmaceuticals
8.5
04-28SeekingAlphaOramed Pharmaceuticals invests $36.9 M in Alpha Tau Medical
Sign Up For More News
People Also Watch
EWCZ
European Wax Center Inc
3.180
USD
-5.36%
RGNX
Regenxbio Inc
9.760
USD
-6.15%
USCB
USCB Financial Holdings Inc
16.700
USD
-2.40%
ENGN
enGene Holdings Inc
3.680
USD
-3.66%
OIS
Oil States International Inc
4.170
USD
-3.70%
SAR
Saratoga Investment Corp
25.010
USD
+0.40%
RIGL
Rigel Pharmaceuticals Inc
19.110
USD
-1.29%
RDUS
Radius Recycling Inc
29.430
USD
0.00%
CWBC
Community West Bancshares
17.870
USD
-0.67%
WTBA
West Bancorporation Inc
19.880
USD
-1.29%
FAQ
What is Alpha Tau Medical Ltd (DRTS) stock price today?
The current price of DRTS is 2.6 USD — it has increased 0.19 % in the last trading day.
What is Alpha Tau Medical Ltd (DRTS)'s business?
What is the price predicton of DRTS Stock?
What is Alpha Tau Medical Ltd (DRTS)'s revenue for the last quarter?
What is Alpha Tau Medical Ltd (DRTS)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Alpha Tau Medical Ltd (DRTS)'s fundamentals?
How many employees does Alpha Tau Medical Ltd (DRTS). have?